Genocea Biosciences (NASDAQ: GNCA) and Eiger BioPharmaceuticals (NASDAQ:EIGR) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, profitability, earnings, analyst recommendations, institutional ownership, dividends and valuation.

Analyst Recommendations

This is a summary of current recommendations and price targets for Genocea Biosciences and Eiger BioPharmaceuticals, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Genocea Biosciences 0 2 3 0 2.60
Eiger BioPharmaceuticals 0 0 4 0 3.00

Genocea Biosciences presently has a consensus price target of $11.90, indicating a potential upside of 554.93%. Eiger BioPharmaceuticals has a consensus price target of $32.60, indicating a potential upside of 161.85%. Given Genocea Biosciences’ higher probable upside, equities analysts clearly believe Genocea Biosciences is more favorable than Eiger BioPharmaceuticals.

Risk & Volatility

Genocea Biosciences has a beta of 2.02, suggesting that its share price is 102% more volatile than the S&P 500. Comparatively, Eiger BioPharmaceuticals has a beta of 2.55, suggesting that its share price is 155% more volatile than the S&P 500.

Earnings and Valuation

This table compares Genocea Biosciences and Eiger BioPharmaceuticals’ revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio EBITDA Earnings Per Share Price/Earnings Ratio
Genocea Biosciences N/A N/A -$54.72 million ($2.03) -0.90
Eiger BioPharmaceuticals N/A N/A -$46.28 million ($5.69) -2.19

Eiger BioPharmaceuticals is trading at a lower price-to-earnings ratio than Genocea Biosciences, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

59.3% of Genocea Biosciences shares are held by institutional investors. Comparatively, 59.9% of Eiger BioPharmaceuticals shares are held by institutional investors. 6.7% of Genocea Biosciences shares are held by insiders. Comparatively, 28.8% of Eiger BioPharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Profitability

This table compares Genocea Biosciences and Eiger BioPharmaceuticals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Genocea Biosciences N/A -146.46% -92.29%
Eiger BioPharmaceuticals N/A -128.94% -88.88%

Summary

Eiger BioPharmaceuticals beats Genocea Biosciences on 8 of the 10 factors compared between the two stocks.

About Genocea Biosciences

Genocea Biosciences, Inc., is harnessing the power of T cell immunity to develop vaccines and immunotherapies company. The Company uses its discovery platform, AnTigen Lead Acquisition System (ATLAS), to design vaccines and immunotherapies that act, in part, through T cell (or cellular) immune responses. The Company has one product candidate in Phase III clinical development, GEN-003, an immunotherapy for the treatment of genital herpes. It also has a pre-clinical immuno-oncology program focused on personalized cancer vaccines (GEN-009). The GEN-009 program leverages ATLAS to identify patient neoantigens, or newly formed antigens unique to each patient, that are associated with that individual’s tumor.

About Eiger BioPharmaceuticals

Eiger BioPharmaceuticals, Inc., formerly Celladon Corporation, is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of products for the treatment of orphan diseases. Its pipeline includes Sarasar (lonafarnib) for hepatitis delta virus (HDV), exendin (9-39) for severe hypoglycemia, and Bestatin (ubenimex) for pulmonary arterial hypertension (PAH) and lymphedema. Lonafarnib is an orally active inhibitor of farnesyl transferase that inhibits the prenylation step of HDV replication inside liver cells and blocks the ability of the virus to multiply. It is conducting over three Phase II clinical trials, which include LOnafarnib With and without Ritonavir (LOWR) HDV-2 (Ankara, Turkey), LOWR HDV-3 (NIH) and LOWR HDV-4 (Hannover, Germany). Exendin is in Phase II clinical studies for the treatment of hypoglycemia associated with bariatric surgery. Ubenimex is in Phase II clinical studies for the treatment of PAH and lymphedema.

Receive News & Stock Ratings for Genocea Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genocea Biosciences Inc. and related stocks with our FREE daily email newsletter.